Durect Corporation Культура компании

Dr. James E. Brown, D.V.M., Co-founded DURECT Corporation in February 1998 and has been its President and Chief Executive Officer since June 1998. Dr. Brown served as Vice President of Biopharmaceutical and Implant Research and Development of ALZA Corporation from June 1995 to June 1998. Dr. Brown held various positions at Syntex Corporation, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown has been a Director of DURECT Corporation since June 1998. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from University of California, Davis where he also conducted post-graduate work in Pharmacology and Toxicology.

Dr. Felix Theeuwes, D.Sc., Ph.D., Co-founded DURECT Corporation in February 1998 and has been its Chairman and Chief Scientific Officer since July 1998. Dr. Theeuwes held various positions at ALZA Corporation from 1970 to June 1999, including President of New Ventures from August 1997 to August 1998, President of ALZA Research and Development from 1995 to August 1997, President of ALZA Technology Institute from 1994 to April 1995 and Chief Scientist from 1982 to June 1997. His work at Alza led to the product introduction of the Alzet??? mini osmotic pump series for animal research and the OROS??? systems series of products. He directed research in transdermal research and development, initiated the electrotransport/ionphoresis program and initiated the DUROS??? osmotic implant program. Dr. Theeuwes serves as Director of Genetronics Inc. He has been a Director of DURECT Corporation since July 1998. He serves as a Member of the board of Directors of Vinifera Inc., and a member of the scientific advisory board at Antigenics. He served as a Director of Tibotec-Virco NV. He served as a Director of Inovio Biomedical Corp. (formerly, Genetronics Biomedical Corporation) from August 1999 to May 4, 2007. Dr. Theeuwes holds more than 210 United States patents covering these systems and has published more than 80 articles and chapters of books. In 1993, he completed the Stanford Executive Program at Palo Alto, California. He also served as a post-doctoral fellow and visiting research assistant professor in the Department of Chemistry at the University of Kansas. Dr. Theeuwes received his undergraduate and graduate education in physics at the Katholieke Unversiteit Leuven (Louvain),Belgium, with a D.Sc. degree in 1966.

Mr. Matthew J. Hogan, also known as Matt, MBA, has been the Chief Financial Officer of DURECT Corporation since September 12, 2006 and serves as its Secretary. Mr. Hogan served as the Chief Financial Officer of Vermillion, Inc. (formerly, Ciphergen Biosystems Inc.) from September 2000 to 2006, Senior Vice President from March 2004 to March 22, 2006, Vice President from September 2000 to March 2004 and served as its Consultant since March 22, 2006. He joined Ciphergen Biosystems Inc. in September 2000. He served as the Chief Financial Officer of Avocet Medical Inc. from June 1999 to 2000. From 1996 to 1999, He served as the Chief Financial Officer at Microcide Pharmaceuticals, Inc. From 1986 to 1996, He served various positions in the investment banking group at Merrill Lynch & Co., and as its Director he focused on the biotechnology and pharmaceutical sectors. Mr. Hogan holds a BA in Economics from Dartmouth College and an MBA from the Amos Tuck School of Business Administration.

Ms. Judy R. Joice has been Senior Vice President of Operations & Corporate Quality Assurance at DURECT Corporation since March 2014 and served as its Vice President of Operations and Corporate Quality Assurance. Ms. Joice joined DURECT in 2007 and has over 25 years experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread and Syntex Research. During her career, she has gained broad experience in developing, implementing and managing all aspects of company-wide quality systems and compliance functions, ranging from drug development through commercial manufacturing. Ms. Joice has a B.S. in Chemistry from California State University.

Dr. Myriam Theeuwes D.D.S has been Senior Vice President of Clinical Development at DURECT Corporation since September 20, 2017. Dr. Theeuwes joined DURECT from Johnson & Johnson where she spent 18 years, worked as Compound Development Team Leader for Janssen Pharmaceutical's global public health initiatives where she led the development and launch of products including SIRTURO'? (bedaquiline), the first drug with a new mechanism of action to treat tuberculosis in over 40 years. Dr. Theeuwes has extensive experience and success in developing pharmaceuticals for both major and rare diseases is an ideal fit with DURECT's pipeline of products. Dr. Theeuwes spent 11 years at ALZA Corporation in positions of increasing responsibility culminating in her appointment as General Manager and Associate Medical Director for Europe. Before her career in industry, Dr. Theeuwes was a practicing resident dentist at the University of California San Francisco (UCSF) and San Marcos Health Center in Honduras. She received her dental degree from the University of Leuven, Belgium and obtained her California state dental license after completing the Advanced General Dentistry Residency Program at UCSF.

Dr. John W. Gibson, B.S. serves as Vice President of Birmingham Operations at DURECT Corporation and serves as its Principal Scientist. Dr. Gibson has over 30 years of pharmaceutical product development experience involving biodegradable excipients and injectable, long-acting formulations. Mr. Gibson joined DURECT in 2001 as Executive Director of Product Development and assumed management Responsibility for DURECT's Birmingham operations in 2005. Prior to joining DURECT, from 1974 to 2000, Mr. Gibson held a variety of technical and management positions with Southern Biosystems, Eastman Chemical Company, Eli Lilly and Company and Southern Research Institute. He has numerous scientific publications and is the inventor of several U.S. and foreign patents. Mr. Gibson received his B.S. and M.S. in Chemistry from the University of Alabama at Birmingham.

Mr. Steve Helmer serves as Chief Patent Counsel and Vice President of DURECT Corporation. Mr. Helmer joined DURECT in 2010. Mr. Helmer has over 17 years of experience as a Patent Attorney. After law school, Mr. Helmer worked at the U.S. Patent and Trademark Office for 2 years and then was a patent attorney at various law firms for the next 8 years. At that point, Mr. Helmer switched over to the corporate side as patent counsel for Nektar Therapeutics for 5 years, followed by one year at Life Technologies prior to joining DURECT. Mr. Helmer received his J.D. from the University of Minnesota Law School (cum laude) and received an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Chemical Engineering from Michigan Technological University (magna cum laude).

Dr. Su IL Yum, Ph.D., has been Executive Vice President of Pharmaceutical Systems Research and Development at DURECT Corporation since January 2007. Dr. Yum served as Senior Vice President of Engineering at DURECT Corporation since December 2003 and also served as its Senior Vice President of Pharmaceutical Systems Research & Development since January 2006. Prior to joining DURECT Corp., he served as a Senior Technical Advisor of Amira Medical, where he participated in the development of a pain free glucose detector called AtLast(R). Prior to joining Amira, he held a number of senior positions in project management and engineering at ALZA Corporation and contributed to the development of a number of ALZA's enabling drug delivery technologies and commercial products, most notably transdermal patch products such as Nicoderm(R) (nicotine patch) and Duragesic(R) (fentanyl patch). He has more than 40 scientific publications and is the inventor of more than 60 U.S. and foreign patents. Dr. Yum earned his Ph.D. degree in Chemical Engineering from the University of Minnesota and completed a Post-doctoral research in Biomedical Engineering at the University of Utah. Dr. Yum is a Fellow of the American Association of Pharmaceutical Scientists.

Dr. Weiqi Lin, M.D., Ph.D. serves as Senior Vice President of Research & Development, R&D Business Development and Principal Scientist of DURECT Corporation and served as its Vice President of Research & Development Business Development. Dr. Lin joined DURECT in and was Vice President, R&D Business Development. Dr. Lin began her career at AlZA, where she worked for 10 years, developing an extensive knowledge of drug delivery systems which has proven invaluable to her role at DURECT. While at ALZA, she was a member of a team which was responsible for product pipeline selection and evaluation. After ALZA and prior to joining DURECT, she was a co-founder of a company and acted as a consultant. As a result, she has over 17 years of experience in industry. After graduation, she worked as a lecturer for 4 years at both Shanghai Medical University and Beijing Medical University. She received her M.D. from Shanghai Medical University, was a visiting scholar at Medical College of Virginia and received her Ph.D. Pharm/Tox from the Medical College of Virginia.